Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “AEROSOLS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources
PubMed1990

Persistence of enhanced aerosol deposition in the lung after recovery from carbachol-induced airway obstruction.

Time course recovery from induced airway obstruction by carbachol infusion (CI; 0.2 microgram.kg-1.min-1 for 40 min), carbachol aerosol (CA; 10 breaths of 2% solution), and histamine aerosol (HA; 25-50 breaths of 5% solution) challenge was investigated in conscious sheep (n = 6 each). Total lung aerosol deposition and airway caliber as assessed by pulmonary airflow resistance (RL) were measured every 20-30 min up to 4 h after the challenges. Aerosol deposition was measured by monitoring aerosol concentration continuously with a laser aerosol photometer while the sheep rebreathed 1.0-micron-diam inert oil droplets delivered by a 0.25-liter bag-in-box system driven by a respiratory pump at a breathing frequency of 30 breaths/min. Total accumulated deposition at the fifth breath (AD5) as percentage of the initial aerosol concentration was determined and used as an aerosol deposition index. Percent changes in AD5 from baseline were compared with corresponding changes in RL. Both RL and AD5 increased after Cl, CA, and HA: 192-477% for RL and 23-44% for AD5 (P less than 0.05). Mean RL return to baseline values 1 h after CI and HA and 2 h after CA. Mean AD5 returned to baseline at 1 h post-HA. In contrast, mean AD5 remained elevated for 2-4 h after CI and CA (P less than 0.05), and the increased AD5 could not be reversed by a bronchodilator aerosol. The persistence of enhanced aerosol deposition long after the return of RL to baseline suggests that complete recovery of airway conditions after CI and CA takes much longer than predicted by RL.(ABSTRACT TRUNCATED AT 250 WORDS)

Aerosols↗
PubMed1999

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.

Intravenous administration of a humanized monoclonal antibody of IgE (E25) attenuates the early and late phase response to inhaled allergen in allergic asthmatic subjects. To test whether direct delivery of E25 to the airway might have the same effect, we conducted a randomized, double-blind, three group study in 33 subjects with mild allergic asthma (20 to 46 yr of age, 21 men, FEV(1) > 70% predicted). The airway responses to aerosolized allergen were determined at baseline, after 2 and 8 wk of once daily treatment with aerosolized placebo (n = 11), aerosolized E25 1 mg (n = 12), or aerosolized E25 10 mg (n = 10), and after 4 wk of treatment withdrawal. We found that E25 was detectable in the serum during aerosol treatment, although serum IgE did not change significantly in any of the three groups during treatment. In addition, both doses of E25 were no more effective than placebo in attenuating the early phase responses to allergen at both times during treatment. Although aerosolized E25 was generally well tolerated, one subject receiving aerosolized E25 10 mg daily was found to have serum IgG and IgA antibodies to E25. We conclude that aerosol administration of an anti-IgE monoclonal antibody does not inhibit the airway responses to inhaled allergen in allergic asthmatic subjects. We speculate that the observed lack of efficacy may be due to the inability of aerosol route of delivery to result in high enough concentrations of E25 in the tissue compartments surrounding IgE effector cells to neutralize IgE arising from local airway and pulmonary sources and IgE arising from the vascular space. Additionally, the aerosol route of delivery of monoclonal antibodies may be more immunogenic than the parenteral route.

Administration, Inhalation↗
PubMed2005

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

INTRODUCTION: The clinical and economic consequences of the emergence of multidrug-resistant Gram-negative bacteria in the intensive care unit (ICU) setting, combined with the high mortality rate among patients with nosocomial pneumonia, have stimulated a search for alternative therapeutic options to treat such infections. The use of adjunctive therapy with aerosolized colistin represents one of these. There is extensive experience with use of aerosolized colistin by patients with cystic fibrosis, but there is a lack of data regarding the use of aerosolized colistin in patients without cystic fibrosis. METHODS: We conducted the present study to assess the safety and effectiveness of aerosolized colistin as an adjunct to intravenous antimicrobial therapy for treatment of Gram-negative nosocomial pneumonia. We retrospectively reviewed the medical records of patients hospitalized in a 450-bed tertiary care hospital during the period from October 2000 to January 2004, and who received aerosolized colistin as adjunctive therapy for multidrug-resistant pneumonia. RESULTS: Eight patients received aerosolized colistin. All patients had been admitted to the ICU, with mean Acute Physiological and Chronic Health Evaluation II scores on the day of ICU admission and on day 1 of aerosolized colistin administration of 14.6 and 17.1, respectively. Six of the eight patients had ventilator-associated pneumonia. The responsible pathogens were Acinetobacter baumannii (in seven out of eight cases) and Pseudomonas aeruginosa (in one out of eight cases) strains. Half of the isolated pathogens were sensitive only to colistin. The daily dose of aerosolized colistin ranged from 1.5 to 6 million IU (divided into three or four doses), and the mean duration of administration was 10.5 days. Seven out of eight patients received concomitant intravenous treatment with colistin or other antimicrobial agents. The pneumonia was observed to respond to treatment in seven out of eight patients (four were cured and three improved [they were transferred to another facility]). One patient deteriorated and died from septic shock and multiple organ failure. Aerosolized colistin was well tolerated by all patients; no bronchoconstriction or chest tightness was reported. CONCLUSION: Aerosolized colistin may be a beneficial adjunctive treatment in the management of nosocomial pneumonia (ventilator associated or not) due to multidrug-resistant Gram-negative bacteria.

Aerosols↗
PubMed2004

Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis.

STUDY OBJECTIVES: Aerosol interferon-gamma (IFN-gamma) is a potential immunomodulator in the treatment of pulmonary tuberculosis (TB). Previous investigations demonstrated conversion of sputum smears in five patients with multidrug-resistant TB after 12 treatments over 1 month, and induction of signaling molecules in 10 of 11 drug-sensitive TB patients using BAL. The objective of the current study was to evaluate particle size and deposition pattern in patients with TB receiving aerosol IFN-gamma treatment. DESIGN: Particle size was determined with a cascade impactor, and deposition of IFN-gamma mixed with (99m)Tc-labeled human serum albumin was assessed using a gamma camera. Local levels of IFN-gamma were measured in BAL using enzyme-linked immunosorbent assays. Study patients/intervention: Fourteen patients with pulmonary TB received IFN-gamma aerosol (500 micro g) for 12 treatments in addition to antimycobacterial therapy with BAL before and after IFN-gamma aerosol treatment. Eight patients with minimal-to-moderate parenchymal involvement underwent deposition studies. Deposited (99m)Tc-labeled IFN-gamma aerosol was partitioned between upper airways and lungs using attenuation correction measurements. (133)Xe equilibrium scanning, (133)Xe washout, and (99m)Tc- macroaggregate injection defined regional lung volume, ventilation, and perfusion. RESULTS: Upper airway deposition was significant often exceeding lung deposition (53.9 +/- 7.09 micro g vs 35.8 +/- 2.73 micro g, respectively [mean +/- SE]). IFN-gamma levels measured in BAL fluid were significantly increased with aerosol treatment (0.83 +/- 0.43 micro g before vs 24.76 +/- 8.71 micro g after, p </= 0.017), and IFN-gamma levels correlated with regional deposition of IFN-gamma aerosol (r = 0.823). Four-quadrant analysis of regional lung deposition best correlated with regional perfusion (r = 0.422, p = 0.013) with penetration of aerosol into areas of obvious radiographic infiltration on chest radiograph. CONCLUSIONS: Aerosol therapy with IFN-gamma in patients with pulmonary TB is widely distributed and results in significant enhancement of IFN-gamma levels in the lower respiratory tract. In patients without lung destruction, IFN-gamma aerosol may be an adjuvant to enhance the local immune response.

Administration, Inhalation↗
PubMed1997

Comparative study of challenge aerosols for performance test for dust respirators.

A comparative study of challenge aerosols was conducted to review a performance test for dust respirators. The national approval test for dust respirator certification in Japan requires that air containing quartz particles of smaller than 2 microns in diameter should be used as the test aerosol. Aerosols with broad size distributions may therefore be used as the test aerosols. In view of the international harmonization of respirator certification standards, it is necessary to use alternative test aerosols for the approval test for dust respirators. The present study was undertaken to measure the collection efficiency of filters by using three kinds of test aerosols, i.e., quartz dust, sodium chloride and dioctyl sebacate mist aerosols. We used the cartridges of dust respirators and filtering facepieces from eight Japanese and foreign manufacturers, all of which have been certified by the national approval test. Good correlation among the measured collection efficiencies was found for the three test aerosols, but penetrations with sodium chloride and dioctyl sebacate mist aerosols were more than 10 times those of quartz dust aerosol.

Aerosols↗
PubMed1987

Generation and characterization of respirable metallic oxide aerosols for pulmonary clearance studies in calves.

An aerosol generating system capable of producing inert, insoluble, non-toxic, respirable, submicronic particles suitable for deposition, retention and clearance studies in the lungs of calves was designed and tested. The machine generated high volume outputs of respirable aerosols by nebulization of an aqueous solution of metallic ions, drying the droplet aerosol, thermal degradation in the presence of oxygen to form insoluble oxides, and subsequent cooling of the aerosol. Aqueous solutions of ferric nitrate, ferric chloride, ferric citrate, ferric oxalate, zinc acetate, lead acetate, cobalt nitrate, cobalt chloride and cobalt acetate were examined, and the resultant aerosols characterized by particle size distribution, shape, aerosol mass concentration, and production of toxic by-products. Iron oxide and cobalt oxide aerosols were judged suitable for inhalation studies in calves, and cobalt oxide was selected for pulmonary clearance studies due to the low background content of cobalt in lung tissue. The cobalt oxide aerosol selected had a geometric mean diameter (GMD) of 0.54 to 0.65 micron with a dimensionless geometric standard deviation (GSD) of 1.41 to 1.71, a mass aerosol concentration of 124 to 335 mg/m3, and a NO2 contamination of 5 to 33 ppm. The cobalt oxide particles were measurably polydisperse, but virtually all particles were smaller than 2.0 microns making the aerosol totally respirable.

Aerosols↗
PubMed1986

Regional comparison of technetium-99m DTPA aerosol and radioactive gas ventilation (xenon and krypton) studies in patients with suspected pulmonary embolism.

The regional distribution of [99mTc]DTPA aerosol was compared with that of 133Xe (n = 30) and krypton (n = 24) in a group of patients with suspected pulmonary embolism. All patients had an aerosol study using a recently available commercial generator system, a ventilation study with one of the gases, and perfusion imaging. Regional information was assessed visually on xenon, krypton, and aerosol studies independently by considering each lung as three equal-sized zones. In addition, gas ventilation findings peripheral to regions of aerosol turbulence ("hot spots") were evaluated. Only 64% of the zones were in complete agreement on xenon and aerosol. Most of the discordance between xenon and aerosol was accounted for by minor degrees of 133Xe washout retention in zones that appeared normal in the aerosol study. An agreement rate of 85% was noted between 81mKr and aerosol regionally. The regions of discordance between aerosol and gas studies, however, usually were associated with unimpressive perfusion defects that did not change the scintigraphic probability for pulmonary embolism in any patient. Regarding zones of aerosol hyperdeposition, 76% had associated washout abnormalities on xenon; however, there was no correlation between the presence of these abnormalities or perfusion abnormalities. The results confirm the high sensitivity of 133Xe washout imaging, but suggest that radioaerosol imaging will detect most parenchymal abnormalities associated with perfusion defects of significance.

Adult↗
PubMed1984

Immunologic responses of calves to aerosolized antigen: humoral response to ovalbumin.

The humoral response of cattle to ovalbumin (OA), a nonenvironmental well-defined antigen, was studied. During 9 weeks of aerosolization, weekly serum and nasal secretion concentrations of immunoglobulin (Ig)G1, IgG2, IgM, IgA, and IgE were determined by enzyme-linked immunosorbent assay (ELISA) for OA specific antibody. Data from 3 calves given aerosol OA were compared and contrasted with data from 3 calves given aerosol saline solution and 1 calf given parenteral OA. The presence of cytotropic (skin sensitizing) antibody was evaluated during weeks 6 and 9 by direct skin testing with OA. A humoral response was induced in all 3 calves given aerosol OA. Serum IgG1 and IgG2 titers reached a maximum of 64,000 and 2,000, respectively, in calves given aerosol OA compared with 521,000 and 16,000, respectively, in the calf given parenteral OA. The ELISA did not detect an OA-specific IgM response. In contrast, all 3 calves given aerosol OA had serum IgA concentrations that increased to a peak by week 9. The mean IgA absorbance value for the 3 calves given aerosol OA was slightly greater than 5 times that of the calf given parenteral OA. Similarly, nasal secretions from calves given aerosolized OA had absorbance values that were 15-fold greater than that from the calf given parenteral OA. Calves given aerosol OA had antigen-specific IgE responses during weeks 6 to 8. The ELISA results were compared with results of passive cutaneous anaphylaxis tests. The presence of skin-sensitizing antibody was indicated by positive skin tests in the calves given aerosol OA and the calf given parenteral OA by week 9.

Aerosols↗
PubMed2002

Development and testing of a detection method for liquid chromatography based on aerosol charging.

Aerosol-based detection methods for HPLC in which HPLC effluent is converted to an aerosol and detected optically have been employed in the past. This paper describes a new aerosol-based detection method for HPLC, which we name aerosol charge detection. This detection method also involves generation of an aerosol but with aerosol detection by charging aerosol particles and measuring the current from the charged particle flux. A commercial electrical aerosol size analyzer was used for the aerosol detection. The constructed detector was tested using flow injection analysis with water as the mobile phase, and the signal response was found to be linear for sodium sulfate over the concentration ranges of 0.2-100 microg mL(-1) using one of the nebulizers. Minimum mass and concentration detection limits using the more efficient nebulizer were estimated to be 0.2 ng and 10 ng mL(-1), respectively. Behavior for most of the other compounds tested was similar with some differences in sensitivity. Testing the detector using reversed phase HPLC for glucose gave a range of linear response and detection limits that were similar to the flow injection analysis studies. Under most HPLC conditions, the noise will primarily be a function of solvent impurities; however, the electrical aerosol size analyzer allows the removal of small charged particles to improve the signal-to-noise ratio.

Journal Article↗
PubMed2005

N(2)O(5) reaction on submicron sea salt aerosol: kinetics, products, and the effect of surface active organics.

The reaction of N(2)O(5) on sea salt aerosol is a sink for atmospheric nitrogen oxides and a source of the Cl radical. We present room-temperature measurements of the N(2)O(5) loss rate on submicron artificial seawater (ASW) aerosol, performed with an entrained aerosol flow tube coupled to a chemical ionization mass spectrometer, as a function of aerosol phase (aqueous or partially crystalline), liquid water content, and size. We also present an analysis of the product growth kinetics showing that ClNO(2) is produced at a rate equal to N(2)O(5) loss, with an estimated lower limit yield of 50% at 50% relative humidity (RH). The reaction probability for N(2)O(5), gamma(N(2)(O)(5)), depends strongly on the particle phase, being 0.005 +/- 0.004 on partially crystalline ASW aerosol at 30% RH and 0.03 +/- 0.008 on aqueous ASW aerosol at 65% RH. At 50% RH, N(2)O(5) loss is relatively insensitive to particle size for radii greater than 100 nm, and gamma(N(2)(O)(5)) displays a statistically insignificant increase from 0.022 to approximately 0.03 for aqueous ASW aerosol over the RH range of 43-70%. We find that the presence of millimolar levels of hexanoic acid in the aerosol bulk decreases the gamma(N(2)(O)(5)) at 70% RH by a factor of 3-4 from approximately 0.025 to 0.008 +/- 0.004. This reduction is likely due to the partitioning of hexanoic acid to the gas-aerosol interface at a surface coverage that we estimate to be equivalent to a monolayer. This result is the first evidence that a monolayer coating of aqueous organic surfactant can slow the reactive uptake of atmospheric trace gases to aerosol.

Journal Article↗
PubMed2006

Reactive uptake of N2O5 by aerosol particles containing mixtures of humic acid and ammonium sulfate.

The kinetics of reactive uptake of N2O5 on submicron aerosol particles containing humic acid and ammonium sulfate has been investigated as a function of relative humidity (RH) and aerosol composition using a laminar flow reactor coupled with a differential mobility analyzer (DMA) to characterize the aerosol. For single-component humic acid aerosol the uptake coefficient, gamma, was found to increase from 2 to 9 x 10(-4) over the range 25-75% RH. These values are 1-2 orders of magnitude below those typically observed for single-component sulfate aerosols (Phys. Chem. Chem. Phys. 2003, 5, 3453-3463;(1) Atmos. Environ. 2000, 34, 2131-2159(2)). For the mixed aerosols, gamma was found to decrease with increasing humic acid mass fraction and increase with increasing RH. For aerosols containing only 6% humic acid by dry mass, a decrease in reactivity of more than a factor of 2 was observed compared with the case for single-component ammonium sulfate. The concentration of liquid water in the aerosol droplets was calculated using the aerosol inorganic model (for the ammonium sulfate component) and a new combined FTIR-DMA system (for the humic acid component). Analysis of the uptake coefficients using the water concentration data shows that the change in reactivity cannot be explained by the change in water content alone. We suggest that, due to its surfactant properties, the main effect of the humic acid is to reduce the mass accommodation coefficient for N2O5 at the aerosol particle surface. This has implications for the use of particle hygroscopicity data for predictions of the rate of N2O5 hydrolysis.

Journal Article↗
PubMed2005

The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination.

Aerosolized medications have been used for centuries to treat respiratory diseases. Until recently, inhalation therapy focused primarily on the treatment of asthma and chronic obstructive pulmonary disease, and the pressurized metered-dose inhaler was the delivery device of choice. However, the role of aerosol therapy is clearly expanding beyond that initial focus. This expansion has been driven by the Montreal protocol and the need to eliminate chlorofluorocarbons (CFCs) from traditional metered-dose inhalers, by the need for delivery devices and formulations that can efficiently and reproducibly target the systemic circulation for the delivery of proteins and peptides, and by developments in medicine that have made it possible to consider curing lung diseases with aerosolized gene therapy and preventing epidemics of influenza and measles with aerosolized vaccines. Each of these drivers has contributed to a decade or more of unprecedented research and innovation that has altered how we think about aerosol delivery and has expanded the role of aerosol therapy into the fields of systemic drug delivery, gene therapy, and vaccination. During this decade of innovation, we have witnessed the coming of age of dry powder inhalers, the development of new soft mist inhalers, and improved pressurized metered-dose inhaler delivery as a result of the replacement of CFC propellants with hydrofluoroalkane. The continued expansion of the role of aerosol therapy will probably depend on demonstration of the safety of this route of administration for drugs that have their targets outside the lung and are administered long term (eg, insulin aerosol), on the development of new drugs and drug carriers that can efficiently target hard-to-reach cell populations within the lungs of patients with disease (eg, patients with cystic fibrosis or lung cancer), and on the development of devices that improve aerosol delivery to infants, so that early intervention in disease processes with aerosol therapy has a high probability of success.

Administration, Inhalation↗
PubMed1995

Propellant-driven aerosols for delivery of proteins in the respiratory tract.

Metered-dose propellant-driven aerosols of an antigenically reactive protein were produced by combining bovine gammaglobulin (BGG) with one of several surfactants soluble in Freon or dimethylether propellants. Small-particle protein aerosols were most effectively produced by lyophilizing surfactants and proteins prior to the addition of propellants. Up to 26% of the total aerosolized protein was of respirable size. Aerosol metering valves delivering small volumes were most effective in producing respirable-sized (< or = 4 micron median mass aerodynamic diameter) protein aerosols. Proteins were suspended in liquified propellants as both propellant-soluble molecules and visible sedimenting clusters which both contributed to making respirable-sized protein aerosol particles. Electron microscopy showed that respirable-sized protein particles were composed of variable-sized chain aggregates of spherical subunits. Proteins were antigenic after suspension in liquified propellant and release as aerosols, but antigenicity diminished with extended propellant exposure. Local immunity in the respiratory tract is a key factor in resistance to respiratory infections. Metered-dose propellant-driven aerosols offer a potentially attractive method for delivering small-particle aerosols of immunizing antigens or other therapeutic proteins to the respiratory tract.

Aerosol Propellants↗
PubMed2006

Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.

BACKGROUND: Lung disease in preterm infants is often complicated with lung edema. OBJECTIVES: The aim of this review is to assess the risks and benefits of aerosolized diuretic administration in preterm infants with or developing chronic lung disease (CLD). Primary objectives are to assess effects on short term outcome (changes in need for oxygen or ventilatory support) and effects on long-term outcome. Secondary objectives are to assess changes in pulmonary mechanics and potential complications of therapy. SEARCH STRATEGY: We used the standard search method of the Cochrane Neonatal Review Group. We used the following keywords: { or } and , limited to and limited to or . We searched MEDLINE (1966 - 1998), EMBASE (1974 - 1998) and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2006). In addition, we hand searched several abstract books of national and international American and European Societies. The search of MEDLINE and of CENTRAL was last updated in March 2006. SELECTION CRITERIA: For the purpose of this analysis, we included trials in which preterm infants with or developing chronic lung disease and at least five days of age were all randomly allocated to receive an aerosolized loop diuretic. Eligible studies needed to assess at least one of the outcome variables defined a priori for this systematic review. Primary outcome variables included need for ventilator support, chronic lung disease, mortality and other important clinical outcomes. Secondary outcome variables included pulmonary mechanics and potential complications of therapy. DATA COLLECTION AND ANALYSIS: We used the standard method for the Cochrane Collaboration which is described in the Cochrane Collaboration Handbook. Two investigators extracted, assessed and coded separately all data for each study, using a form that was designed specifically for this review. Any disagreement was resolved by discussion. We combined parallel and cross-over trials and, whenever possible, transformed baseline and final outcome data measured on a continuous scale into change scores using Follmann's formula. MAIN RESULTS: We identified eight studies that met selection criteria. Most studies focused on pathophysiological parameters and did not assess effects on important clinical outcomes defined in this review or the potential complications of diuretic therapy. No study assessed the amount of diuretic effectively delivered to the patient. Furosemide was the only diuretic used in the eight studies included in this review. Among preterm infants < 3 weeks of age developing CLD, not enough information is available to assess the effect of aerosolized furosemide on outcome or lung function. Among infants > 3 weeks with CLD, a single aerosolized dose of 1 mg/kg of furosemide may transiently improve pulmonary mechanics. Not enough information is available to assess the effect of chronic administration of aerosolized furosemide on oxygenation and pulmonary mechanics. AUTHORS' CONCLUSIONS: In preterm infants > 3 weeks with CLD administration of a single dose of aerosolized furosemide improves pulmonary mechanics. In view of the lack of data from randomized trials concerning effects on important clinical outcomes, routine or sustained use of aerosolized loop diuretics in infants with (or developing) CLD cannot be recommended based on current evidence.More double-blinded randomized trials are needed (1) to analyze factors likely to affect the response to aerosolized furosemide, e.g., washout period and delivery of furosemide to distal airways, and (2) to assess the effects of chronic administration of aerosolized furosemide on mortality, O2 dependency, ventilator dependency, length of hospital stay and long-term outcome.

Aerosols↗
PubMed2005

Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application.

BACKGROUND: Polyethylenimine (PEI) has been successfully used for gene delivery to the lungs of mice via aerosol application using a whole body nebulization device. In this report we optimized the design of such an aerosol device. METHODS: Aerosol devices were constructed as either serial inhalation apparatus or as a whole body nebulization chamber connected to an aerosol spacer placed in a horizontal or vertical position. PEI-based gene vectors were nebulized using a standard jet nebulizer and luciferase gene expression of various tissues was examined. RESULTS: Using a whole body aerosol device resulted in luciferase gene expression in the lungs of mice at the same level as compared with a serial inhalation apparatus. Whereas gene expression was enhanced in the presence of 5% CO(2)-in-air, anesthesia of mice strongly decreased gene expression even when mice were intubated with an intravascular cannula. Reduction of the median mass aerodynamic diameter (MMAD) of the aerosol from 3.4 to 0.27 microm by interposition of an aerosol spacer increased gene expression significantly 3-fold. Drying of the aerosol by silica gel additionally increased gene delivery significantly 3-fold. Reporter gene expression mediated by branched PEI 25 kDa was 9- and 15-fold higher as compared with linear PEIs of 22 and 25 kDa, respectively, and was dependent on the DNA concentration. Gene expression was detectable as soon as 6 h after gene vector application and reached a maximum after 72 h but was still detectable after 14 days. The presence of Zn(2+) did not increase gene expression. CONCLUSION: We propose aerosol drying as a novel and simple method of optimizing PEI-based gene delivery to the lungs.

Aerosols↗
PubMed1984

Effect of environmental factors on aerosol-induced Lassa virus infection.

Previous studies suggested that the most frequent means of transmission of Lassa virus was by either direct or indirect contact with infectious material. Aerosol stability and respiratory infectivity of the Josiah strain of Lassa virus were assessed to determine the effect of environmental factors on aerosol-induced infection. The stability of the virus in aerosol, particularly at low relative humidity (30% RH), plus the ability of the virus to infect guinea pigs and monkeys via the respiratory route emphasize the potential for aerosol transmission of Lassa virus. Biological half-lives at both 24 and 32 degrees C ranged from 10.1 to 54.6 min, and were sufficient for aerosol dispersion of virus to considerable distances in natural situations. Infectivity of Lassa virus in small particle aerosol was demonstrated in outbred guinea pigs and cynomolgus monkeys using dynamic aerosol equipment. Monkeys exposed to inhaled doses to 465 PFU were infected and died. The median infectious dose (ID50) for guinea pigs was 15 PFU, yet a definitive median lethal aerosol dose (LD50) could not be established. Organ tropism of aerosol-induced Lassa virus infections in outbred guinea pigs was similar to that previously reported for inbred guinea pigs infected by subcutaneous inoculation.

Aerosols↗
PubMed1980

Effect of low and high relative humidity on metered-dose bronchodilator solution and powder aerosols.

Physical properties of two metered-dose bronchodilator aerosols packaged as solutions and two aerosols packaged as finely ground powders were measured at low and high relative humidity. The aerodynamic size distribution and particle concentration were measured in real time using the single-particle aerodynamic relaxation time analyzer, which can measure the aerodynamic diameter of single suspended particles in the respirable size range. The count median aerodynamic diameter, the mass per dose were calculated. Significant increases were noted in the count median aerodynamic diameter, the total particles per dose, and the total aerodynamic mass median aerodynamic diameter for three aerosols and in the mass median aerodynamic diameter for two aerosols. The number of particles in the measured size range increased 3.6- and 4.1-fold for the droplet aerosols and 1.4-fold for the powder preparations. The aerodynamic mass per dose in the measured size range increased 5.7- and 11.4-fold for the droplet aerosols and 3.1- and 1.6-fold for the powder aerosols. These data indicate that all aerosols tested increased in size at high humidity and that aerosols dispensed as droplets may be more unstable than those dispensed as powders.

Aerosols↗
PubMed1993

Potential species dependency for the pulmonary antiallergic effects of aerosolized heparin.

The inhibition of antigen aerosol-induced bronchoconstriction by heparin aerosol pretreatment has been demonstrated in conscious sheep. Therefore, we investigated the effect of heparin aerosol pretreatment on antigen aerosol-induced bronchoconstriction in anaesthetized and ventilated guinea-pigs. In one study all animals were pretreated with propranolol and indomethacin in order to produce a large bronchoconstriction, whereas in a second study this pretreatment was omitted in order to produce a smaller bronchoconstriction. In both studies aerosolized heparin failed to inhibit antigen aerosol-induced bronchoconstriction, whether delivered at 1, 10 and 100 mg/ml 10 min prior to antigen challenge or delivered at 50 mg/ml 60 min prior to antigen challenge. In contrast, salbutamol aerosol pretreatment (1 mg/ml, delivered 10 min prior to antigen challenge) produced a near-maximum inhibition of antigen aerosol-induced bronchoconstriction. These results suggest that the pulmonary antiallergic effects of aerosolized heparin are potentially species dependent.

Administration, Inhalation↗